de Crevoisier R, Castelli J, Guérif S, Pommier P, Créhange G, Chauvet B, Lagrange J L
Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, avenue Bataille-Flandres-Dunkerque, 35042 Rennes cedex, France; Laboratoire traitement du signal et de l'image, université de Rennes 1, campus de Beaulieu, bâtiment 22, 35042 Rennes cedex, France; Inserm U 642, 35042 Rennes cedex, France.
Département de radiothérapie, centre régional de lutte contre le cancer Eugène-Marquis, avenue Bataille-Flandres-Dunkerque, 35042 Rennes cedex, France; Laboratoire traitement du signal et de l'image, université de Rennes 1, campus de Beaulieu, bâtiment 22, 35042 Rennes cedex, France; Inserm U 642, 35042 Rennes cedex, France.
Cancer Radiother. 2014 Oct;18(5-6):369-78. doi: 10.1016/j.canrad.2014.07.154. Epub 2014 Sep 6.
The identification of the optimal radiation technique in prostate cancer is based on the results of dosimetric and clinical studies, although there are almost no randomized studies comparing different radiation techniques. The feasibility of the techniques depends also on the technical and human resources of the radiation department, on the cost of the treatment from the points of view of the society, the patient and the radiation oncologist, and finally on the choice of the patient. The slow evolution of prostate cancer leads to consider the biochemical failure as the main judgment criteria in the majority of the studies. A proper urinary radio-induced toxicity evaluation implies a long follow-up. Intensity-modulated radiotherapy (IMRT) combined with image-guided radiotherapy (IGRT) is recommended in case of high dose (≥76Gy) to the prostate, pelvic lymph nodes irradiation and hypofractionation schedules. For low-risk tumors, the aim of the treatment is to preserve quality of life, while limiting costs. Stereotactic body radiotherapy shows promising results, although the follow-up is still limited and phase III trials are ongoing. Focal radiation techniques are in the step of feasibility. For intermediate and high-risk tumors, the objective of the treatment is to increase the locoregional control, while limiting the toxicity. IMRT combined with IGRT leads to either a well-validated dose escalation strategy for intermediate risk tumors, or to a strategy of moderate hypofractionated schedules, which cannot be yet considered as a standard treatment. These combined radiation techniques allow finally large lymph node target volume irradiation and dose escalation potentially in the dominant intraprostatic lesion. The feasibility of simultaneous integrated boost approaches is demonstrated.
前列腺癌最佳放疗技术的确定基于剂量学和临床研究结果,尽管几乎没有比较不同放疗技术的随机研究。这些技术的可行性还取决于放疗科室的技术和人力资源、从社会、患者和放疗肿瘤学家角度看的治疗成本,以及最终患者的选择。前列腺癌进展缓慢,这使得在大多数研究中把生化失败作为主要判断标准。恰当的放射性泌尿毒性评估需要长期随访。对于前列腺高剂量(≥76Gy)、盆腔淋巴结照射和大分割放疗方案,推荐采用调强放疗(IMRT)联合图像引导放疗(IGRT)。对于低危肿瘤,治疗目的是在限制成本的同时保留生活质量。立体定向体部放疗显示出有前景的结果,尽管随访仍有限且Ⅲ期试验正在进行。局部放疗技术正处于可行性研究阶段。对于中高危肿瘤,治疗目标是在限制毒性的同时提高局部区域控制率。IMRT联合IGRT对于中危肿瘤而言,要么是一种经过充分验证的剂量递增策略,要么是一种中等大分割放疗方案策略,后者尚不能被视为标准治疗。这些联合放疗技术最终能够实现对大的淋巴结靶区体积的照射,并有可能增加前列腺内主要病灶的剂量。同步整合加量方法的可行性已得到证实。